Skip to main content

Domainex

  • About
    • About
    • Case Studies
    • Testimonials
    • Awards
    • Board members
    • Investors
    • Management team
    • Contact us
  • Services
    • Offerings
      • Integrated Drug Discovery Services
      • Protein Expression and Purification Services
      • X-ray crystallography
      • Assay Development
      • Biophysical Assays
      • Biochemical Assays
      • Synthetic Chemistry
      • Virtual screening
      • Fragment and Compound Screening
      • Computational Chemistry
      • Medicinal Chemistry
      • Cell Based Assays
      • ADME and Bioanalytical Sciences
      • Analytical Chemistry
    • Research Phases
      • Hit Identification
      • Hit to Lead
      • Lead Optimisation
    • Therapeutic Areas
      • Oncology
      • Immuno-Oncology
      • Cardiovascular
      • Respiratory
      • Anti-infectives
      • Inflammatory diseases
      • CNS Drug Discovery
    • Target Classes
      • Kinases
      • GPCRs
      • Proteases
      • Methyltransferases
      • Ion Channels
      • Protein-Protein Interactions
    • Approaches & Techniques
      • CDH (Target Gene Fragmentation)
      • PoLiPa (Membrane Protein Solubilisation)
      • LeadBuilder
      • FragmentBuilder
      • Fragment Based Drug Discovery (FBDD)
      • Structure Based Drug Design (SBDD)
      • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
      • Grating-Coupled Interferometry
      • High Throughput Screening
      • MicroScale Thermophoresis (MST) Services
      • Targeted Protein Degradation
  • Library
    • Articles
    • Brochures
    • Newsletters
    • Posters
    • Presentations & Videos
    • Publications
    • White Papers
  • News & Events
  • Careers
  • English
  • French
  • Spanish
  • German
  • Italian
  • Japanese
  • Dutch
Enquire

ON Helix

Breadcrumb

  1. Home
Thursday, 7 Jul '22

Domainex will be attending ON Helix in person. The one-day conference will address the main bio innovation trends, from the developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments.

 

News

NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project

30 Jun '22
Press Release

Meet the Domainex Team: Nima Abbasian

14 Jun '22
Blog Post

Synthesis in Review: Allylic tertiary amines and hetero-functionalised 2-oxazolines

9 Jun '22
Blog Post

A Talk by Professor Marcus Baumann — Continuous Flow Synthesis

1 Jun '22
Blog Post

OBN BioTuesday at the Rosalind Franklin Institute

26 May '22
Blog Post

33rd Medicinal Chemistry in Eastern England

17 May '22
Blog Post
View more

Upcoming Events

Jul 7 ON Helix

Jul 7 Innovative New Pharma and Biotech Partnerships: How is the landscape transforming?

Sep 4 XXVll EFMC International Symposium on Medicinal Chemistry

View more

Start your next project with Domainex

Contact one of our experts today
Domainex
  • About
    • About
    • Case Studies
    • Testimonials
    • Awards
    • Board members
    • Investors
    • Management team
    • Contact us
  • Services
    • Offerings
      • Integrated Drug Discovery Services
      • Protein Expression and Purification Services
      • X-ray crystallography
      • Assay Development
      • Biophysical Assays
      • Biochemical Assays
      • Synthetic Chemistry
      • Virtual screening
      • Fragment and Compound Screening
      • Computational Chemistry
      • Medicinal Chemistry
      • Cell Based Assays
      • ADME and Bioanalytical Sciences
      • Analytical Chemistry
    • Research Phases
      • Hit Identification
      • Hit to Lead
      • Lead Optimisation
    • Therapeutic Areas
      • Oncology
      • Immuno-Oncology
      • Cardiovascular
      • Respiratory
      • Anti-infectives
      • Inflammatory diseases
      • CNS Drug Discovery
    • Target Classes
      • Kinases
      • GPCRs
      • Proteases
      • Methyltransferases
      • Ion Channels
      • Protein-Protein Interactions
    • Approaches & Techniques
      • CDH (Target Gene Fragmentation)
      • PoLiPa (Membrane Protein Solubilisation)
      • LeadBuilder
      • FragmentBuilder
      • Fragment Based Drug Discovery (FBDD)
      • Structure Based Drug Design (SBDD)
      • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
      • Grating-Coupled Interferometry
      • High Throughput Screening
      • MicroScale Thermophoresis (MST) Services
      • Targeted Protein Degradation
  • Library
    • Articles
    • Brochures
    • Newsletters
    • Posters
    • Presentations & Videos
    • Publications
    • White Papers
  • News & Events
  • Careers
COVID-19

+44 (0) 1223 743170 enquiries@domainex.co.uk

Offerings

  • Protein Expression and Purification Services
  • X-Ray crystallography
  • Biochemical Assays
  • Biophysical Assays
  • Assay Development
  • Fragment and Compound Screening
  • Cell Based Assays
  • Medicinal Chemistry
  • Synthetic Chemistry
  • Computational Chemistry
  • Analytical Chemistry
  • ADME and Bioanalytical Sciences

Research Phases

  • Lead Optimisation
  • Hit to Lead
  • Hit Identification

Therapeutic Areas

  • Oncology
  • Immuno-Oncology
  • Cardiovascular
  • Respiratory Disease
  • Anti-infectives
  • Inflammatory diseases
  • CNS Drug Discovery

Target Classes

  • Kinases
  • GPCRs
  • Proteases
  • Protein Methyltransferases
  • Ion Channels
  • Protein-Protein Interactions

Approaches & Techniques

  • CDH (Target Gene Fragmentation)
  • LeadBuilder – Virtual Screening
  • FragmentBuilder: Fragment-Based Drug Discovery and Design
  • Innovative Polymer Lipid Particle (PoLiPa) Technology
  • Structure Based Drug Design (SBDD)
  • Ligand binding assays by Surface Plasmon Resonance (SPR) and/or Grating-Coupled Interferometry (GCI)
  • MicroScale Thermophoresis (MST) Services
  • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
  • High Throughput Screening
  • Targeted Protein Degradation

Domainex is a registered company (number 4336899)

Site and its contents Copyright © Domainex 2022. All rights reserved.